Erkko Ylösmäki

E-postadresserkko.ylosmakihelsinkifi

Forskningsoutput per år

Vetenskapsgrenar

3111 Biomedicinska vetenskaper
317 Farmaci

24 Artikel
4 Mötesabstrakt
3 Översiktsartikel
2 Kapitel
Mer
- 1 Doktorsavhandling

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines
Feola, S., Chiaro, J., Fusciello, M., Russo, S., Kleino, I., Ylösmäki, L., Kekäläinen, E., Hästbacka, J., Pekkarinen, P. T., Ylösmäki, E., Capone, S., Folgori, A., Raggioli, A., Boni, C., Tiezzi, C., Vecchi, A., Gelzo, M., Kared, H., Nardin, A. & Fehlings, M. & 8 andra, Barban, V., Ahokas, P., Viitala, T., Castaldo, G., Pastore, L., Porter, P., Pesonen, S. & Cerullo, V., mars 2024, I: International Journal of Biological Macromolecules. 262, 16 s., 129926.
Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Öppen tillgång
Fil
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
Hamdan, F., Feodoroff, M., Russo, S., Fusciello, M., Feola, S., Chiaro, J., Antignani, G., Greco, F., Leusen, J., Ylösmaki, E., Grönholm, M. & Cerullo, V., 16 mars 2023, I: Molecular Therapy - Oncolytics. 28, s. 264-276 13 s.
Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Öppen tillgång
Fil
A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
Fusciello, M., Ylösmäki, E., Feola, S., Uoti, A., Martins, B., Aalto, K., Hamdan, F., Chiaro, J., Russo, S., Viitala, T. & Cerullo, V., 16 juni 2022, I: Molecular Therapy - Oncolytics. 25, s. 137-145 9 s.
Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Öppen tillgång
Fil
A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines
Feola, S., Chiaro, J., Martins, B., Russo, S., Fusciello, M., Ylösmäki, E., Bonini, C., Ruggiero, E., Hamdan, F., Feodoroff, M., Antignani, G., Viitala, T., Pesonen, S., Grönholm, M., Branca, R. M. M., Lehtiö, J. & Cerullo, V., 22 mars 2022, I: eLife. 11, 21 s., 71156.
Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Öppen tillgång
Fil
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment
Feola, S., Russo, S., Ylösmäki, E. & Cerullo, V., aug. 2022, I: Pharmacology & Therapeutics. 236, 13 s., 108103.
Forskningsoutput: Tidskriftsbidrag › Översiktsartikel › Peer review

Öppen tillgång
Fil

Erkko Ylösmäki

Personlig profil

Vetenskapsgrenar

Samarbeten och ledande forskningsområden under de senaste fem åren

Fördjupning

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment

Erkko Ylösmäki

Personlig profil

Vetenskapsgrenar

Samarbeten och ledande forskningsområden under de senaste fem åren

Forskningsresultat

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment